Novome is a biotechnology company focused on engineering first-in-class, living medicines for chronic diseases.
Novome is developing engineered cellular therapies for the gut to treat chronic diseases.
Novome was founded in 2016 by Will DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ. The company is headquartered in South San Francisco, California.
Novome has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs).
Novome is utilizing its proprietary GEMMs platform in its proof-of-concept program in enteric hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to decrease the risk of kidney stone formation.
Novome has also made significant progress with earlier-stage programs enabling local delivery of high amounts of therapeutic protein cargo for the potential treatment of inflammatory bowel disease. Efforts are also directed toward advancing additional pipeline indications in irritable bowel syndrome and immuno-oncology.
Novome is backed by Tencent, DCVC Bio, 5AM Ventures, Alta Partners, Alexandria Venture Investments, Mayo Clinic, University of Minnesota, Navian Investments, Colorcon Ventures, and others. The company raised $43.5M in Series B round on Sep 13, 2022. This brings Novome's total funding to $81.5M to date.